ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.77%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$616M
AUM Growth
+$616M
(+19%)
Cap. Flow
+$33.1M
Cap. Flow
% of AUM
5.37%
Top 10 Holdings %
Top 10 Hldgs %
49.49%
Holding
239
New
40
Increased
61
Reduced
56
Closed
33
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$52.1M |
| 2 |
Prothena Corp
PRTA
|
$20.5M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 4 |
CytomX Therapeutics
CTMX
|
$6.89M |
| 5 |
ABVX
Abivax
ABVX
|
$6.59M |
Top Sells
| 1 |
RAPT Therapeutics
RAPT
|
$41.5M |
| 2 |
Roivant Sciences
ROIV
|
$17.4M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$8.63M |
| 4 |
Immunovant
IMVT
|
$6.94M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
Sector Composition
| 1 | Healthcare | 83.61% |
| 2 | Financials | 2.95% |
| 3 | Consumer Discretionary | 0% |
| 4 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Xilio Therapeutics
XLO
$36.3M
| – | – |
-40,000
| Closed | -$29K |
|
227
Zymeworks
ZYME
$1.12B
| – | – |
-50,000
| Closed | -$596K |
|
228
Iron Horse Acquisitions Corp. Warrant
IROHW
$351K
| – | – |
-25,000
| Closed | -$800 |
|
|
JVSA
229
DELISTED
JV SPAC Acquisition Corp
JVSA
| – | – |
-30,000
| Closed | -$322K |
|
|
ATYR
230
aTyr Pharma
ATYR
$527M
| – | – |
0
| – | – |
|
|
ADGM
231
Adagio Medical Holdings, Inc Common Stock
ADGM
$24.8M
| – | – |
-76,757
| Closed | -$61.8K |
|
|
UPB
232
Upstream Bio, Inc. Common Stock
UPB
$923M
| – | – |
-15,000
| Closed | -$91.8K |
|
|
SPRB
233
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| – | – |
-403,716
| Closed | -$117K |
|
|
ITCI
234
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-48,044
| Closed | -$6.34M |
|
|
AACT
235
Ares Acquisition Corporation II
AACT
$706M
| – | – |
-90,466
| Closed | -$1.01M |
|